JP2017530195A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017530195A5 JP2017530195A5 JP2017536991A JP2017536991A JP2017530195A5 JP 2017530195 A5 JP2017530195 A5 JP 2017530195A5 JP 2017536991 A JP2017536991 A JP 2017536991A JP 2017536991 A JP2017536991 A JP 2017536991A JP 2017530195 A5 JP2017530195 A5 JP 2017530195A5
- Authority
- JP
- Japan
- Prior art keywords
- rivastigmine
- formulation
- aqueous
- nasal
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020036966A JP7357571B2 (ja) | 2014-10-03 | 2020-03-04 | 神経学的及び神経変性疾患及び障害を処置するための鼻腔投与組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2014903944A AU2014903944A0 (en) | 2014-10-03 | Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders | |
| AU2014903944 | 2014-10-03 | ||
| PCT/AU2015/050591 WO2016049700A1 (en) | 2014-10-03 | 2015-09-30 | Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020036966A Division JP7357571B2 (ja) | 2014-10-03 | 2020-03-04 | 神経学的及び神経変性疾患及び障害を処置するための鼻腔投与組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017530195A JP2017530195A (ja) | 2017-10-12 |
| JP2017530195A5 true JP2017530195A5 (enExample) | 2018-11-08 |
Family
ID=55629161
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017536991A Pending JP2017530195A (ja) | 2014-10-03 | 2015-09-30 | 神経学的及び神経変性疾患及び障害を処置するための鼻腔投与組成物 |
| JP2020036966A Active JP7357571B2 (ja) | 2014-10-03 | 2020-03-04 | 神経学的及び神経変性疾患及び障害を処置するための鼻腔投与組成物 |
| JP2021171712A Pending JP2022003100A (ja) | 2014-10-03 | 2021-10-20 | 神経学的及び神経変性疾患及び障害を処置するための鼻腔投与組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020036966A Active JP7357571B2 (ja) | 2014-10-03 | 2020-03-04 | 神経学的及び神経変性疾患及び障害を処置するための鼻腔投与組成物 |
| JP2021171712A Pending JP2022003100A (ja) | 2014-10-03 | 2021-10-20 | 神経学的及び神経変性疾患及び障害を処置するための鼻腔投与組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10471040B2 (enExample) |
| EP (1) | EP3200828B1 (enExample) |
| JP (3) | JP2017530195A (enExample) |
| AU (1) | AU2015327762C1 (enExample) |
| CA (1) | CA2961936C (enExample) |
| DK (1) | DK3200828T3 (enExample) |
| ES (1) | ES2822562T3 (enExample) |
| HU (1) | HUE052441T2 (enExample) |
| PL (1) | PL3200828T3 (enExample) |
| PT (1) | PT3200828T (enExample) |
| SM (1) | SMT202000576T1 (enExample) |
| WO (1) | WO2016049700A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3200828T3 (pl) * | 2014-10-03 | 2021-01-25 | Lachesis Biosciences Limited | Kompozycje donosowe do leczenia chorób i zaburzeń neurologicznych i neurodegeneracyjnych |
| LT3474850T (lt) * | 2017-02-02 | 2020-08-10 | Otolanum Ag | Intranazalinė kompozicija, apimanti betahistiną |
| EP4171542A4 (en) * | 2020-06-25 | 2024-07-24 | Lachesis Biosciences Limited | METHODS FOR TREATING OR PREVENTING ORGANOPHOSPHORUS POISONING |
| WO2022029604A1 (en) * | 2020-08-07 | 2022-02-10 | Council For Scientific And Industrial Research | Microemulsion drug delivery system for treatment of acute respiratory distress syndrome |
| CA3193558A1 (en) * | 2020-10-01 | 2022-04-07 | Lyra Therapeutics, Inc. | Osmotic drug delivery implants |
| CN115919767B (zh) * | 2022-10-13 | 2023-08-11 | 暨南大学 | 卡巴拉汀鼻喷雾剂及其制备方法 |
| CN119523898A (zh) * | 2024-12-02 | 2025-02-28 | 肇庆学院 | 多靶点药物的经鼻给药制剂及其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR5733M (enExample) | 1966-09-27 | 1968-01-22 | ||
| US4806543A (en) | 1986-11-25 | 1989-02-21 | Board Of Trustees Of The Leland Stanford Junior University | Method and compositions for reducing neurotoxic injury |
| FR2722989B1 (fr) | 1994-07-29 | 1997-05-30 | Synthelabo | Utilisation de l'ifenprodil et de ses enantiomeres pour la preparation de medicaments utiles dans le traitement des neuropathies peripheriques et des maladies neurodegeneratives centrales |
| US6558560B2 (en) * | 2001-07-27 | 2003-05-06 | Hewlett-Packard Company | Method for the fabrication of electrical contacts |
| WO2004034963A2 (en) * | 2002-05-17 | 2004-04-29 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
| US20040254146A1 (en) * | 2002-05-21 | 2004-12-16 | Nastech Pharmaceutical Company Inc. | Carboxylate salts of galantamine and their pharmaceutical use |
| US20030225031A1 (en) * | 2002-05-21 | 2003-12-04 | Quay Steven C. | Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid |
| EP2153824A1 (en) * | 2004-09-27 | 2010-02-17 | Sigmoid Pharma Limited | Seamless multiparticulate formulations |
| US8058291B2 (en) * | 2005-04-06 | 2011-11-15 | Adamas Pharmaceuticals, Inc. | Methods and compositions for the treatment of CNS-related conditions |
| US8187570B1 (en) * | 2005-01-04 | 2012-05-29 | Gp Medical, Inc. | Nanoparticles for protein drug delivery |
| US8911751B2 (en) * | 2005-10-11 | 2014-12-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions for nasal delivery |
| CN101325944B (zh) * | 2005-10-11 | 2013-01-16 | 耶路撒冷希伯来大学伊萨姆研究开发公司 | 用于鼻部给药的组合物 |
| AU2007212586A1 (en) * | 2006-02-03 | 2007-08-16 | Avanir Pharmaceuticals | Pharmaceutical compositions for treating depression, anxiety and neurodegenerative disorders |
| AR059358A1 (es) * | 2006-02-09 | 2008-03-26 | Schering Corp | Formulaciones farmaceuticas |
| US20100197811A1 (en) * | 2007-06-26 | 2010-08-05 | Hidekazu Suzuki | Aqueous composition |
| FR2931677B1 (fr) * | 2008-06-02 | 2010-08-20 | Sanofi Aventis | Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs |
| KR20180101641A (ko) | 2010-05-17 | 2018-09-12 | 포럼 파마슈티칼즈 인크. | (R)-7-클로로-N-(퀴누클리딘-3-일)벤조[b]티오펜-2-카르복사미드 히드로클로리드 모노히드레이트의 결정질 형태 |
| US8673338B2 (en) * | 2011-07-29 | 2014-03-18 | Massachusetts Eye And Ear Infirmary | Methods of delivering pharmaceutical agents |
| PL3200828T3 (pl) * | 2014-10-03 | 2021-01-25 | Lachesis Biosciences Limited | Kompozycje donosowe do leczenia chorób i zaburzeń neurologicznych i neurodegeneracyjnych |
-
2015
- 2015-09-30 PL PL15848100T patent/PL3200828T3/pl unknown
- 2015-09-30 JP JP2017536991A patent/JP2017530195A/ja active Pending
- 2015-09-30 EP EP15848100.2A patent/EP3200828B1/en active Active
- 2015-09-30 WO PCT/AU2015/050591 patent/WO2016049700A1/en not_active Ceased
- 2015-09-30 HU HUE15848100A patent/HUE052441T2/hu unknown
- 2015-09-30 SM SM20200576T patent/SMT202000576T1/it unknown
- 2015-09-30 ES ES15848100T patent/ES2822562T3/es active Active
- 2015-09-30 DK DK15848100.2T patent/DK3200828T3/da active
- 2015-09-30 PT PT158481002T patent/PT3200828T/pt unknown
- 2015-09-30 US US15/516,233 patent/US10471040B2/en active Active
- 2015-09-30 CA CA2961936A patent/CA2961936C/en active Active
- 2015-09-30 AU AU2015327762A patent/AU2015327762C1/en active Active
-
2019
- 2019-09-13 US US16/569,986 patent/US10933045B2/en active Active
-
2020
- 2020-03-04 JP JP2020036966A patent/JP7357571B2/ja active Active
-
2021
- 2021-01-27 US US17/160,009 patent/US11911360B2/en active Active
- 2021-10-20 JP JP2021171712A patent/JP2022003100A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017530195A5 (enExample) | ||
| JP6657454B2 (ja) | ブプレノルフィンの乱用抵抗性粘膜付着性送達デバイス | |
| KR102489453B1 (ko) | 비강내 제약 분말 조성물 | |
| WO2020086673A1 (en) | Ketamine oral transmucosal delivery system | |
| JP2018517676A5 (enExample) | ||
| JP2016512833A (ja) | ウイルス感染症の治療薬としてのベラプロスト異性体 | |
| TW201016209A (en) | Intranasal compositions, dosage forms and methods of treatments | |
| JP2016525548A5 (enExample) | ||
| WO2013081565A1 (en) | Pharmaceutical compositions comprising roflumilast and terbutaline | |
| JP5775970B2 (ja) | 口腔貼付剤 | |
| JP2008518007A5 (enExample) | ||
| JP2023545372A (ja) | デクスメデトミジン塩酸塩を用いた双極性障害及び精神病の治療 | |
| CN1735434A (zh) | 用于预防和治疗伤风与类流感症状的包含精选粘附聚合物的组合物 | |
| JP2016502991A5 (enExample) | ||
| JP5624472B2 (ja) | ロペラミド塩酸塩含有フィルム製剤 | |
| JP2013253038A (ja) | 口腔内溶解型フィルム製剤 | |
| CN108024952A (zh) | 在治疗发作中用于口颊施用以获得快速起效的咪达唑仑组合物 | |
| CN114585364B (zh) | 谷氨酸2b受体拮抗剂和σ受体激动剂作为止咳药的用途 | |
| CN105106250B (zh) | 一种灵芝总三萜组合物及其制备方法 | |
| JP2014525891A5 (enExample) | ||
| Rajab et al. | Influence of tamarind seed gum derivatives on the in vitro performance of gastro-retentive tablets based on hydroxypropylmethylcellulose | |
| CN111971034A (zh) | 一种含格隆铵盐的气雾剂药物组合物及其制备方法与应用 | |
| JP2015515971A5 (enExample) | ||
| JP2012072133A (ja) | 塩酸アンブロキソールの小型徐放性製剤 | |
| JP2011251954A (ja) | 安全弁を有する経口フィルム製剤 |